Influenza vaccination

New England Journal of Medicine

Volumn 375, Issue 13, 2016, Pages 1261-1268

  Treanor, John J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE; VIRUS SIALIDASE; INACTIVATED VACCINE; LIVE VACCINE;

ANTIBODY RESPONSE; ARTICLE; CASE CONTROL STUDY; CLINICAL STUDY; COHORT ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; EMULSION; HUMAN; IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INJECTION SITE PAIN; NONHUMAN; OBSERVATIONAL STUDY; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; AGED; IMMUNOLOGY; INFLUENZA, HUMAN; MALE;

AGED; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PRACTICE GUIDELINES AS TOPIC; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84990028191     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1512870     Document Type: Article

References (42)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitaliza-tions in the United States. JAMA 2004; 292:1333-40.
2. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012;54:1427-36.
3. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One 2015; 10(3): e0118369.
4. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161: 441-6.
5. Morgan OW, Bramley A, Fowlkes A, et al. Morbid obesity as a risk factor for hos-pitalization and death due to 2009 pandemic inf luenza A(H1N1) disease. PLoS One 2010;5(3):e9694.
6. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 inf luenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303: 1517-25.
7. Louie JK, Acosta M, Jamieson DJ, Ho-nein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362: 27-35.
8. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 2013; 62(RR-07):1-43.
9. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2016-17 influenza season. MMWR Morb Recomm Rep 2016; 65: 1-54.
10. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008; 66: 655-63.
11. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51: 997-1004.
12. Treanor JJ, El Sahly H, King J Jr, et al. Protective efficacy of a trivalent recombi-nant hemagglutinin protein vaccine (Flu-Blok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011;29:7733-9.
13. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavi-rus vaccine in children. N Engl J Med 1998;338:1405-12.
14. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:36-44.
15. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355: 2513-22.
16. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357: 1373-81.
17. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vac-cination and reduction in hospitaliza-tions for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348:1322-32.
18. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993;270:1956-61.
19. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006;35:345-52.
20. Orenstein EW, De Serres G, Haber MJ, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007; 36: 623-31.
21. Seasonal influenza vaccine effectiveness, 2005-2016. Atlanta: Centers for Disease Control and Prevention, 2016 (http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm).
22. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, dou-ble-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80.
23. DiazGranados CA, Dunning AJ, Kim-mel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371: 635-45.
24. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015; 15: 293-300.
25. Richardson DM, Medvedeva EL, Roberts CB, Linkin DR. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis 2015; 61: 171-6.
26. Van Buynder PG, Konrad S, Van Buyn-der JL, et al. The comparative effectiveness of adjuvanted and unadjuvanted tri-valent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31: 6122-8.
27. Treanor J. Weathering the influenza vaccine crisis. N Engl J Med 2004; 351: 2037-40.
28. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013;56:1363-9.
29. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Di s 2014;58:319-27.
30. McLean HQ, Thompson MG, Sundar-am ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014; 59: 1375-85.
31. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: as-sessments of prior vaccination and sero-logic susceptibility. J Infect Dis 2015; 211: 1519-28.
32. Skowronski DM, Chambers C, Sabai-duc S, et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season. Clin Infect Dis 2016;63:21-32.
33. Mosterín Höpping A, McElhaney J, Fonville JM, Powers DC, Beyer WEP, Smith DJ. The confounded effects of age and exposure history in response to influ-enza vaccination. Vaccine 2016; 34: 540-6.
34. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 1999; 96: 14001-6.
35. Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vac-cine. Pediatrics 2016; 137(2): e20153279.
36. Kashyap AK, Steel J, Oner AF, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 2008;105:5986-91.
37. Wrammert J, Koutsonanos D, Li G-M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208: 181-93.
38. Ekiert DC, Bhabha G, Elsliger M-A, et al. Antibody recognition of a highly con-served influenza virus epitope. Science 2009;324:246-51.
39. Ekiert DC, Friesen RHE, Bhabha G, et al. A highly conserved neutralizing epit-ope on group 2 influenza A viruses. Science 2011;333:843-50.
40. Sui J, Sheehan J, Hwang WC, et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 2011; 52: 1003-9.
41. Margine I, Hai R, Albrecht RA, et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 2013; 87: 472 8-37.
42. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013; 64: 189-202.